
    
      Randomized (stratified on diabetes), placebo-controlled, double-blind, parallel-assignment,
      dose-range multicenter study

      There are 3 parallel treatment groups: placebo, IVA337 800mg once a day (Quaque Die, QD) and
      IVA337 1200mg QD (identical tablets of 400mg IVA337 or placebo). Both, patient and
      investigator are blinded.

      For each patient, the study duration will be an overall of 6 to 8 months (with a 10-day to
      4-week selection period, a 24-week treatment period and a 4-week follow-up period).
    
  